Stay updated with breaking news from Graphite Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) – Research analysts at Cantor Fitzgerald decreased their FY2023 earnings per share (EPS) estimates for Graphite Bio in a research report issued on Tuesday, May 16th. Cantor Fitzgerald analyst O. Brayer now forecasts that the company will post earnings per share of ($0.99) for the year, down from […]
Novel approach combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single...
Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML... | May 10, 2023
Shares of Graphite Bio, Inc. (NASDAQ:GRPH – Get Rating) have been given an average rating of “Hold” by the nine analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and eight have given a hold rating to the company. The average 1-year price target among […]
In this article, we will take a look at the 12 gene editing stocks with the best long-term potential.